DrugPatentWatch Database Preview
Details for New Drug Application (NDA): 207318
NDA 207318 describes NUPLAZID, which is a drug marketed by Acadia Pharms Inc and is included in one NDA. It is available from one supplier. There are fourteen patents protecting this drug. Additional details are available on the NUPLAZID profile page.
The generic ingredient in NUPLAZID is pimavanserin tartrate. One supplier is listed for this compound. Additional details are available on the pimavanserin tartrate profile page.
The generic ingredient in NUPLAZID is pimavanserin tartrate. One supplier is listed for this compound. Additional details are available on the pimavanserin tartrate profile page.
Summary for 207318
| Tradename: | NUPLAZID |
| Applicant: | Acadia Pharms Inc |
| Ingredient: | pimavanserin tartrate |
| Patents: | 14 |
Suppliers and Packaging for NDA: 207318
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| NUPLAZID | pimavanserin tartrate | TABLET;ORAL | 207318 | NDA | ACADIA Pharmaceuticals Inc | 63090-170 | N | 63090-170-60 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | EQ 17MG BASE | ||||
| Approval Date: | Apr 29, 2016 | TE: | RLD: | Yes | |||||
| Regulatory Exclusivity Expiration: | Apr 29, 2021 | ||||||||
| Regulatory Exclusivity Use: | NEW CHEMICAL ENTITY | ||||||||
| Patent: | ➤ Try a Free Trial | Patent Expiration: | Mar 6, 2021 | Product Flag? | Y | Substance Flag? | Y | Delist Request? | |
| Patent: | ➤ Try a Free Trial | Patent Expiration: | Mar 6, 2021 | Product Flag? | Y | Substance Flag? | Y | Delist Request? | |
| Patented Use: | TREATMENT OF PSYCHOSIS | ||||||||
Complete Access Available with Subscription
